Guest editorial: Protecting thyroid cancer patients from untoward effects of radioactive iodine treatment

Thyroid

Volumn 19, Issue 9, 2009, Pages 925-928

  Kloos, Richard T ^a,b  

^a OHIO STATE UNIVERSITY   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIFOSTINE; IODINE 131; RADIOACTIVE IODINE; RADIOPROTECTIVE AGENT;

CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CLINICAL TRIAL; EDITORIAL; HUMAN; HYPOTHYROIDISM; PRIORITY JOURNAL; RADIATION DOSE; RADIATION PROTECTION; THYROID CANCER; DRUG EFFECT; NOTE; RADIATION EXPOSURE; SALIVARY GLAND; SALIVATION; THYROID TUMOR;

HUMANS; IODINE RADIOISOTOPES; RADIATION-PROTECTIVE AGENTS; RADIOTHERAPY DOSAGE; SALIVARY GLANDS; SALIVATION; THYROID NEOPLASMS;

EID: 70349130817     PISSN: 10507256     EISSN: None     Source Type: Journal    
DOI: 10.1089/thy.2009.0236     Document Type: Editorial

References (40)

1. Seidlin SM, Marinelli LD, Oshry E 1946 Radioactive iodine therapy: Effect on functioning metastases of adenocarcinoma of thyroid. JAMA 132:838-847.
2. Becker DV, Sawin CT 1996 Radioiodine and thyroid disease: The beginning. Semin Nucl Med 26:155-164.
3. Halnan KE 1965 The place of non-surgical methods in diagnosis and management, and the long-term value of treatment of thyroid cancer. Br J Surg 52:736-739.
4. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Pacini F, Schlumberger M, Sherman SI, Steward DL, Tuttle RM 2009 Revised management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid: Submitted.
5. Maenpaa HO, Heikkonen J, Vaalavirta L, Tenhunen M, Joensuu H 2008 Low vs. high radioiodine activity to ablate the thyroid after thyroidectomy for cancer: A randomized study. PLoS One 3:e1885.
6. Pilli T, Brianzoni E, Capoccetti F, Castagna MG, Fattori S, Poggiu A, Rossi G, Ferretti F, Guarino E, Burroni L, Vattimo A, Cipri C, Pacini F 2007 A comparison of 1850 (50 mCi) and 3700 MBq (100 mCi) 131-iodine administered doses for recombinant thyrotropin-stimulated postoperative thyroid remnant ablation in differentiated thyroid cancer. J Clin Endocrinol Metab 92:3542-3546.
7. Pacini F, Ladenson PW, Schlumberger M, Driedger A, Luster M, Kloos RT, Sherman S, Haugen B, Corone C, Molinaro E, Elisei R, Ceccarelli C, Pinchera A, Wahl RL, Leboulleux S, Ricard M, Yoo J, Busaidy NL, Delpassand E, Hanscheid H, Felbinger R, Lassmann M, Reiners C 2006 Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: Results of an international, randomized, controlled study. J Clin Endocrinol Metab 91:926-932.
8. Taieb D, Sebag F, Cherenko M, Baumstarck-Barrau K, For-tanier C, Farman A, De Micco C, Vaillant J, Thomas S, Conte-Devolx B, Loundou A, Auquier P, Henry J, Mundler O 2009 Quality of life changes and clinical outcomes in thyroid cancer patients undergoing radioiodine remnant ablation with recombinant human thyrotropin: A randomized controlled study. Clin Endocrinol (Oxf ) 71:115-123.
9. Elisei R, Schlumberger M, Driedger A, Reiners C, Kloos RT, Sherman SI, Haugen B, Corone C, Molinaro E, Grasso L, Leboulleux S, Rachinsky I, Luster M, Lassmann M, Busaidy NL, Wahl R, Pacini F, Cho SY, Magner J, Pinchera A, Ladenson PW 2009 Follow-up of low-risk differentiated thyroid cancer patients who underwent radioiodine ablation of postsurgical thyroid remnants after either recombinant human thyrotropin or thyroid hormone withdrawal. J Clin Endocrinol Metab: in press.
10. Hanscheid H, Lassmann M, Luster M, Kloos RT, Reiners C 2009 Blood dosimetry from a single measurement of the whole body radioiodine retention in patients with differentiated thyroid carcinoma. Endocr Relat Cancer: 2009 Jul 23 [Epub ahead of print].
11. Bohuslavizki KH, Klutmann S, Brenner W, Mester J, Henze E, Clausen M 1998 Salivary gland protection by amifostine in high-dose radioiodine treatment: Results of a double-blind placebo-controlled study. J Clin Oncol 16:3542-3549.
12. Mendoza A, Shaffer B, Karakla D, Mason ME, Elkins D, Goffman TE 2004 Quality of life with well-differentiated thyroid cancer: Treatment toxicities and their reduction. Thyroid 14:133-140.
13. Kim SJ, Choi HY, Kim IJ, Kim YK, Jun S, Nam HY, Kim JS 2008 Limited cytoprotective effects of amifostine in high-dose radioactive iodine 131-treated well-differentiated thyroid cancer patients: Analysis of quantitative salivary scan. Thyroid 18:325-331.
14. Levy HA, Park CH 1987 Effect of reserpine on salivary gland radioiodine uptake in thyroid cancer. Clin Nucl Med 12:303-307.
15. Nakada K, Ishibashi T, Takei T, Hirata K, Shinohara K, Katoh S, Zhao S, Tamaki N, Noguchi Y, Noguchi S 2005 Does lemon candy decrease salivary gland damage after radioiodine therapy for thyroid cancer? J Nucl Med 46:261-266.
16. Lam MG, van Isselt JW 2005 Re: Does lemon candy decrease salivary gland damage after radioiodine therapy for thyroid cancer? J Nucl Med 46:2118-2119.
17. Van Nostrand D, Atkins F, Bandaru VV, Chennupati SP, Moreau S, Burman K, Wartofsky L 2009 Salivary gland protection with sialagogues: A case study. Thyroid 19:1005-1008.
18. Mandel SJ, Mandel L 2003 Radioactive iodine and the salivary glands. Thyroid 13:265-271.
19. Shen DH, Kloos RT, Mazzaferri EL, Jhiang SM 2001 Sodium iodide symporter in health and disease. Thyroid 11:415-425.
20. Leonard JP, Siegel JA, Goldsmith SJ 2003 Comparative physical and pharmacologic characteristics of iodine-131 and yttrium-90: Implications for radioimmunotherapy for patients with non-Hodgkin's lymphoma. Cancer Invest 21:241-252.
21. Alexander C, Bader JB, Schaefer A, Finke C, Kirsch CM 1998 Intermediate and long-term side effects of high-dose radio-iodine therapy for thyroid carcinoma. J Nucl Med 39:1551-1554.
22. Sawka AM, Thabane L, Parlea L, Ibrahim-Zada I, Tsang RW, Brierley JD, Straus S, Ezzat S, Goldstein DP 2009 Second primary malignancy risk after radioactive iodine treatment for thyroid cancer: A systematic review and meta-analysis. Thyroid 19:451-457.
23. Van Nostrand D, Neutze J, Atkins F 1986 Side effects of "rational dose" iodine-131 therapy for metastatic well-differentiated thyroid carcinoma. J Nucl Med 27:1519-1527.
24. Rosario PW, Borges MA, Purisch S 2008 Preparation with recombinant human thyroid-stimulating hormone for thyroid remnant ablation with 131I is associated with lowered radiotoxicity. J Nucl Med 49:1776-1782.
25. Burns JA, Morgenstern KE, Cahill KV, Foster JA, Jhiang SM, Kloos RT 2004 Nasolacrimal obstruction secondary to I(131) therapy. Ophthal Plast Reconstr Surg 20:126-129.
26. Kloos RT, Duvuuri V, Jhiang SM, Cahill KV, Foster JA, Burns JA 2002 Nasolacrimal drainage system obstruction from radioactive iodine therapy for thyroid carcinoma. J Clin Endocrinol Metab 87:5817-5820.
27. Morgenstern KE, Vadysirisack DD, Zhang Z, Cahill KV, Foster JA, Burns JA, Kloos RT, Jhiang SM 2005 Expression of sodium iodide symporter in the lacrimal drainage system: Implication for the mechanism underlying nasolacrimal duct obstruction in I131-treated patients. Ophthal Plast Reconstr Surg 21:337-344.
28. Solans R, Bosch JA, Galofre P, Porta F, Rosello J, Selva-O'Callagan A, Vilardell M 2001 Salivary and lacrimal gland dysfunction (sicca syndrome) after radioiodine therapy. J Nucl Med 42:738-743.
29. Zettinig G, Hanselmayer G, Fueger BJ, Hofmann A, Pirich C, Nepp J, Dudczak R 2002 Long-term impairment of the lacrimal glands after radioiodine therapy: A cross-sectional study. Eur J Nucl Med Mol Imaging 29:1428-1432.
30. Kita T, Yokoyama K, Higuchi T, Kinuya S, Taki J, Nakajima K, Michigishi T, Tonami N 2004 Multifactorial analysis on the short-term side effects occurring within 96 hours after radioiodine-131 therapy for differentiated thyroid carcinoma. Ann Nucl Med 18:345-349.
31. Caglar M, Tuncel M, Alpar R 2002 Scintigraphic evaluation of salivary gland dysfunction in patients with thyroid cancer after radioiodine treatment. Clin Nucl Med 27:767-771.
32. Malpani BL, Samuel AM, Ray S 1996 Quantification of salivary gland function in thyroid cancer patients treated with radioiodine. Int J Radiat Oncol Biol Phys 35:535-540.
33. Albrecht HH, Creutzig H 1976 [Salivary gland scintigraphy after radio-iodine therapy. Functional scintigraphy of the salivary gland after high dose radio-iodine therapy (author's transl)]. Rofo 125:546-551. (In German.)
34. Lee J, Sogutlu G, Leard L, Zarnegar R, Bailey J, Golden J, Hays S, Kebebew E, Duh QY, Clark O 2007 Lung transplantation for pulmonary metastases and radiation-induced pulmonary fibrosis after radioactive iodine ablation of extensive lung metastases from papillary thyroid carcinoma. Thyroid 17:367-369.
35. Benua RS, Cicale NR, Sonenberg M, Rawson RW 1962 The relation of radioiodine dosimetry to results and complications in the treatment of metastatic thyroid cancer. Am J Roentgenol Radium Ther Nucl Med 87:171-178.
36. Wang W, Larson SM, Tuttle RM, Kalaigian H, Kolbert K, Sonenberg M, Robbins RJ 2001 Resistance of [18F]-flourodeoxyglucose-avid metastatic thyroid cancer lesions to treatment with high-dose radioactive iodine. Thyroid 11: 1169-1175.
37. Robbins RJ, Wan Q, Grewal RK, Reibke R, Gonen M, Strauss HW, Tuttle RM, Drucker W, Larson SM 2006 Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F]fluoro-2-deoxy-D-glucose-positron emission tomography scanning. J Clin Endocrinol Metab 91:498-505.
38. Smallridge RC, Marlow LA, Copland JA 2009 Anaplastic thyroid cancer: Molecular pathogenesis and emerging therapies. Endocr Relat Cancer 16:17-44.
39. Kloos RT, Eng C, Evans DB, Francis GL, Gagel RF, Gharib H, Moley JF, Pacini F, Ringel MD, Schlumberger M, Wells SA, Jr. 2009 Medullary thyroid cancer: Management guidelines of the American Thyroid Association. Thyroid 19:565-612.
40. Hanscheid H, Lassmann M, Luster M, Thomas SR, Pacini F, Ceccarelli C, Ladenson PW, Wahl RL, Schlumberger M, Ri-card M, Driedger A, Kloos RT, Sherman SI, Haugen BR, Carriere V, Corone C, Reiners C 2006 Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: Procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal. J Nucl Med 47:648-654.